Literature DB >> 26181829

Latest concepts on the association between nonsteroidal anti-inflammatory drug-induced small intestinal injury and intestinal bacterial flora.

Shunji Fujimori1, Choitsu Sakamoto2.   

Abstract

Luminal bacteria, one of the main aggressive factors of nonsteroidal anti-inflammatory drugs (NSAIDs), induce small intestinal mucosal injury. Because most bacteria invading from the mouth are eliminated by the highly acidic gastric environment, the upper small intestine contains relatively low numbers of microorganisms. With decreased peristalsis, decreased acidity, and lower oxidation-reduction potential, the ileum maintains a more diverse microflora and a higher bacterial population. As NSAID-induced small intestinal ulcerations tend to localize in the small intestinal distal part, as viewed by capsule endoscopy, the ulcers are in contact with a large amount of luminal bacteria. Recently, it was reported that proton-pump inhibitors (PPIs) exacerbate NSAID-induced small intestinal injury in rats. The study showed that PPIs impair the ability to disinfect due to the PPI-induced low acidic gastric environment, and this resulted in transubstantiation of intestinal flora which exacerbated NSAID-induced small intestinal injury. If it is true that PPIs exacerbate small intestinal injury, the methods of preventing NSAID-induced gastroduodenal injury to defend PPI-induced small intestinal injury should be reconsidered. Following several studies, there may be a possibility that probiotics and prebiotics are useful treatments for the prevention of NSAID-induced small intestinal injury. A method of determining bacterial flora maintenance including alteration of the environment and the administration of various drugs is required.

Entities:  

Keywords:  Bacteria; Flora; NSAID; PPI; Small intestine

Year:  2013        PMID: 26181829     DOI: 10.1007/s12328-013-0424-8

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  47 in total

1.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.

Authors:  P Gionchetti; F Rizzello; A Venturi; P Brigidi; D Matteuzzi; G Bazzocchi; G Poggioli; M Miglioli; M Campieri
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

Review 2.  Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors.

Authors:  Brendan J R Whittle
Journal:  Eur J Pharmacol       Date:  2004-10-01       Impact factor: 4.432

3.  Distribution of small intestinal mucosal injuries as a result of NSAID administration.

Authors:  Shunji Fujimori; Katya Gudis; Yoko Takahashi; Tsuguhiko Seo; Yukie Yamada; Akihito Ehara; Tsuyoshi Kobayashi; Keigo Mitsui; Masaoki Yonezawa; Shu Tanaka; Atsushi Tatsuguchi; Choitsu Sakamoto
Journal:  Eur J Clin Invest       Date:  2010-04-14       Impact factor: 4.686

Review 4.  NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.

Authors:  Angel Lanas; Angel Ferrandez
Journal:  Chin J Dig Dis       Date:  2006

Review 5.  Prevention of traditional NSAID-induced small intestinal injury: recent preliminary studies using capsule endoscopy.

Authors:  Shunji Fujimori; Yoko Takahashi; Tsuguhiko Seo; Katya Gudis; Akihito Ehara; Tsuyoshi Kobayashi; Keigo Mitsui; Masaoki Yonezawa; Shu Tanaka; Atsushi Tatsuguchi; Choitsu Sakamoto
Journal:  Digestion       Date:  2010-06-25       Impact factor: 3.216

6.  Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study.

Authors:  Hiroki Endo; Takuma Higurashi; Kunihiro Hosono; Eiji Sakai; Yusuke Sekino; Hiroshi Iida; Yasunari Sakamoto; Tomoko Koide; Hirokazu Takahashi; Masato Yoneda; Chikako Tokoro; Masahiko Inamori; Yasunobu Abe; Atsushi Nakajima
Journal:  J Gastroenterol       Date:  2011-05-10       Impact factor: 7.527

7.  Total enteroscopy with a nonsurgical steerable double-balloon method.

Authors:  H Yamamoto; Y Sekine; Y Sato; T Higashizawa; T Miyata; S Iino; K Ido; K Sugano
Journal:  Gastrointest Endosc       Date:  2001-02       Impact factor: 9.427

8.  Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial.

Authors:  E Furrie; S Macfarlane; A Kennedy; J H Cummings; S V Walsh; D A O'neil; G T Macfarlane
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

9.  Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration.

Authors:  R Langenbach; S G Morham; H F Tiano; C D Loftin; B I Ghanayem; P C Chulada; J F Mahler; C A Lee; E H Goulding; K D Kluckman; H S Kim; O Smithies
Journal:  Cell       Date:  1995-11-03       Impact factor: 41.582

10.  Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis.

Authors:  Hideki Ishikawa; Ikuko Akedo; Yoshinori Umesaki; Ryuichiro Tanaka; Akemi Imaoka; Toru Otani
Journal:  J Am Coll Nutr       Date:  2003-02       Impact factor: 3.169

View more
  1 in total

1.  Effects of pentasa-combined probiotics on the microflora structure and prognosis of patients with inflammatory bowel disease.

Authors:  Hua Fan; Juan Du; Xia Liu; Wei-Wei Zheng; Ze-Hao Zhuang; Cheng-Dang Wang; Rui Gao
Journal:  Turk J Gastroenterol       Date:  2019-08       Impact factor: 1.852

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.